BECN1 and nasopharyngeal carcinoma: High expression of Beclin-1 has been reported in ovarian cancer [10], GC [11, 12], nasopharyngeal carcinoma [13], intrahepatic cholangiocarcinoma [14], while low expression has been reported in hepatocellular carcinoma [15] and colorectal cancer [16].